A novel immunotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)

被引：0
|
作者：
Saini, Uksha
Hixon, Julie
Rodrigues, Gisele
Foley, Christopher
Chibas, Leniher Castan
Hamilton, Ross
Li, Wenqing
Schafer, Eric S.
Rheingold, Susan
Heffernan, Michael
Breitfeld, Philip
Durum, Scott
Varadhachary, Atul
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5664
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Brivio, Erica
    Hoogendijk, Raoull
    Chantrain, Christophe
    Rialland, Fanny
    Contet, Audrey
    Elitzur, Sarah
    Dalla-Pozza, Luciano
    Kallay, Krisztian
    Li, Chi Kong
    Kato, Motohiro
    Markova, Inna V.
    Schmiegelow, Kjeld
    Bodmer, Nicole
    Pieters, Rob
    Zwaan, Christian Michel
    BLOOD, 2019, 134
  • [32] Efficacy and safety of fludarabine combined with cytarabine in the treatment of patients with relapsed and refractory acute lymphoblastic leukemia (ALL).
    Jiang, B
    Wang, W
    Bao, L
    Huang, XJ
    Lu, J
    Wang, DB
    Lu, DP
    BLOOD, 2005, 106 (11) : 227B - 227B
  • [33] Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
    Badar, Talha
    Szabo, Aniko
    Dinner, Shira
    Liedtke, Michaela
    Burkart, Madelyn
    Shallis, Rory M.
    Yurkiewicz, Ilana R.
    Kuo, Eric
    Khan, Muhammad Ali
    Balasubramanian, Suresh
    Yang, Jay
    Hefazi, Mehrdad
    Podoltsev, Nikolai
    Patel, Anand
    Curran, Emily
    Wang, Amy
    Arslan, Shukaib
    Aldoss, Ibrahim
    Siebenaller, Caitlin
    Mattison, Ryan J.
    Litzow, Mark R.
    Wadleigh, Martha
    Advani, Anjali S.
    Atallah, Ehab
    CANCER, 2021, 127 (07) : 1039 - 1048
  • [34] Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
    Bhatla, Teena
    Hogan, Laura E.
    Teachey, David T.
    Bautista, Francisco
    Moppett, John
    Puyo, Pablo Velasco
    Micalizzi, Concetta
    Rossig, Claudia
    Shukla, Neerav
    Gilad, Gil
    Locatelli, Franco
    Baruchel, Andre
    Zwaan, C. Michel
    Bezler, Natalie S.
    Rubio-San-Simon, Alba
    Taussig, David C.
    Raetz, Elizabeth A.
    Mao, Zhengwei J.
    Wood, Brent L.
    Arias, Diana Alvarez
    Krevvata, Maria
    Nnane, Ivo
    Bandyopadhyay, Nibedita
    Solano, Lorena Lopez
    Dennis, Robyn M.
    Carson, Robin
    Vora, Ajay
    BLOOD, 2024, 144 (21)
  • [35] Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
    Ganzel, Chezi
    Kharit, Mira
    Duksin, Chen
    Rowe, Jacob M.
    HAEMATOLOGICA, 2018, 103 (10) : E489 - E490
  • [36] Bortezomib Combined Chemotherapy for Children with Relapsed/refractory Acute Lymphoblastic Leukemia
    Sakaguchi, Hirotoshi
    Maemura, Ryo
    Yamamori, Ayako
    Wakamatsu, Manabu
    Yoshida, Nao
    Kato, Koji
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S89 - S90
  • [37] Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomibbased chemotherapy
    Zhao, Junmei
    Wang, Chao
    Song, Yongping
    Liu, Yuzhang
    Fang, Baijun
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2015, 8 : 211 - 214
  • [38] Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis
    Heatley, Susan L.
    Page, Elyse C.
    Eadie, Laura N.
    McClure, Barbara J.
    Rehn, Jacqueline
    Yeung, David T.
    Osborn, Michael Philip
    Revesz, Tamas
    Kirby, Maria
    White, Deborah L.
    BLOOD, 2021, 138
  • [39] Trial initiated for liposomal vincristine in relapsed/refractory acute lymphoblastic leukemia
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (10): : 1292 - 1292
  • [40] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
12345